Combination extends survival vs. standard first-line therapy for ...
18 hours ago · Previously reported results showed the combination conferred a 30% reduction in risk for disease progression or death compared with osimertinib (median PFS, 23.7 months vs. 16.6 months; HR = 0.7 ...
Amivantamab/Lazertinib Show OS Improvement for mNSCLC Over Osimertinib
3 days ago · Amivantamab-vmjw (Rybrevant) plus lazertinib (Lazcluze) demonstrated clinically meaningful and statistically significant improvement in overall survival (OS) over the standard-of-care (SOC) osimertinib (Tagrisso) as a first-line therapy for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or L858R mutations, according to a news ...
Amivantamab Plus Lazertinib Improves OS in EGFR-Mutant …
3 days ago · Amivantamab plus lazertinib prolonged overall survival vs osimertinib as first-line therapy in locally advanced or metastatic, EGFR-mutant NSCLC. News OncClub All Oncology News
Osimertinib Improves Survival in Lung Cancer - NCI
Jul 5, 2023 · Osimertinib, which is taken daily as a pill, specifically targets and kills lung cancer cells with these genetic mutations. In the nearly 700-patient study, people who were randomly assigned to receive osimertinib after surgery to remove their tumor(s)—known as adjuvant therapy — lived substantially longer overall than people assigned to ...
FDA approves osimertinib for non-small cell lung cancer
On September 25, 2024, the FDA approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer.
Savolitinib Plus Osimertinib Receives Priority Review in China for ...
Jan 2, 2025 · Study on savolitinib combined with osimertinib in treatment of advanced NSCLC with MET amplification (SACHI). ClinicalTrials.gov. Updated March 30, 2023. Accessed January 2, 2025. https ...
Osimertinib - latest research news and features - Medical Xpress
Sep 9, 2024 · Osimertinib was the first drug to be approved for adjuvant treatment after complete tumor resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC). In an early benefit ...
FDA Approves Osimertinib With Chemotherapy for - ASCO Post
Feb 19, 2024 · On February 16, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso) with platinum-based chemotherapy for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
Study Shows Osimertinib Improves Survival Following Surgery for …
Jun 4, 2023 · A new study led by Yale Cancer Center shows improved rates of survival and reduced risk of recurrence in patients with non-small cell lung cancer taking osimertinib (TAGRISSO), a targeted therapy, following surgery.
FDA approves osimertinib with chemotherapy for EGFR-mutated …
On February 16, 2024, the Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) with platinum-based chemotherapy for patients with locally advanced or...
- Some results have been removed